Clinical-development joint venture commended for staff growth and
WILMINGTON, N.C. & TOKYO–(BUSINESS WIRE)–PPD-SNBL,
the joint venture of Pharmaceutical Product Development, LLC (PPD), a
leading global contract research organization (CRO), and Shin Nippon
Biomedical Laboratories Ltd., one of the largest clinical development
service providers in Japan, has been named a top-five growth business
and desirable employer by Randstad Japan.
In recognizing PPD-SNBL’s rapid growth, Randstad Japan, a subsidiary of
Randstad N.V., a global leader in the human resources services industry,
commended PPD-SNBL for its success with staff growth and retention. The
recognition, announced in its Growing
Companies Research 2019, is based on a survey of more than 7,000
respondents in the Tokyo metropolitan area conducted by a third-party
“Our joint venture, coupling PPD’s global capabilities with SNBL’s depth
of clinical knowledge and scope within Japan, has catapulted us to the
forefront of the CRO industry in the country, and enabled us to attract
and retain exceptional talent,” said Sebastian Pacios, M.D., senior vice
president, clinical development.
Toshihiko Seki, chief financial officer of PPD-SNBL, said, “Our success
results from three factors: holding employee turnover to 4-7 percent
since the joint venture’s formation; continuing to grow our workforce
every year; and placing strong emphasis on the Japanese philosophy that
treating employees as a family is the core of bonding a workforce. We
are excited about this recognition by Randstad and look forward to our
PPD-SNBL’s recognition by Randstad was based on an evaluation of
multiple criteria, the most important being the continuous growth of
employee headcount through recruitment and retention.
“PPD-SNBL was able to accomplish this over the past several years in the
difficult Japanese recruiting market,” said Goro Nakayama, chief
marketing officer of Randstad Japan.
With offices in Tokyo, Osaka and Kagoshima, PPD-SNBL brings together
PPD’s global resources and clinical trial expertise with SNBL’s nearly
20-year history and in-depth knowledge of providing clinical
development services in Japan.
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and lifecycle
management services. Our clients and partners include pharmaceutical,
biotechnology, medical device, academic and government organizations.
With offices in 48 countries and more than 21,000 professionals
worldwide, PPD applies innovative technologies, therapeutic expertise
and a firm commitment to quality to help clients and partners bend the
cost and time curve of drug development and optimize value in delivering
life-changing therapies to improve health. For more information, visit www.ppdi.com.
Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a Japanese global
business that works in pre-clinical research, clinical pharmacology
research, pharmacokinetics and analysis, and translational research.
SNBL has over 1,700 employees in Japan, North America, Europe and other
parts of Asia. Since being founded as Japan’s first contract research
organization in 1957, SNBL has supported clients by committing to
freeing patients from suffering by supporting drug development and
improving medical technology. SNBL is a listed company on the first
section of the Tokyo Stock Exchange. For more information, visit https://www.snbljapan.com.
+1 919 456 6398
+1 910 558 6783
+81 3 5565 6216
+81 99 294 2600